{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:02:06Z","timestamp":1779908526580,"version":"3.53.1"},"reference-count":55,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2675851","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:02:13Z","timestamp":1779904933000},"page":"1555-1564","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Budget impact analysis of delgocitinib for moderate to severe Chronic Hand Eczema in the United States"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3632-9593","authenticated-orcid":false,"given":"Jianni","family":"Singh-Landa","sequence":"first","affiliation":[{"name":"FIECON Ltd","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6620-0716","authenticated-orcid":false,"given":"Aseel","family":"Bin Sawad","sequence":"additional","affiliation":[{"name":"LEO Pharma Inc","place":["Madison, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3433-8768","authenticated-orcid":false,"given":"Yasmin","family":"Bappoo","sequence":"additional","affiliation":[{"name":"FIECON Ltd","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Llewellyn","sequence":"additional","affiliation":[{"name":"FIECON Ltd","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-3262","authenticated-orcid":false,"given":"Megan","family":"Barnes","sequence":"additional","affiliation":[{"name":"FIECON Ltd","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-4436","authenticated-orcid":false,"given":"Douglas","family":"Maslin","sequence":"additional","affiliation":[{"name":"LEO Pharma Inc","place":["Madison, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1957-3692","authenticated-orcid":false,"given":"Sanjeev","family":"Balu","sequence":"additional","affiliation":[{"name":"LEO Pharma Inc","place":["Madison, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14035"},{"key":"e_1_3_8_3_1","volume-title":"2025 Fall Clinical Dermatology Conference, Las Vegas, NV, USA","author":"Chovatiya R","year":"2025","unstructured":"Chovatiya R, Balu S, Sawad A, et al. Prevalence of self-reported physician diagnosis of Chronic Hand Eczema in adults: a cross-sectional study of more than 10,000 participants in the general population \u2013Results from the CHECK study in the United States. 2025 Fall Clinical Dermatology Conference, Las Vegas, NV, USA; 2025"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01164-5"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42596"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21037"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.11.1053"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00669-6"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10427.x"},{"key":"e_1_3_8_10_1","volume-title":"Health care visits and out-of-pocket costs in people with chronic hand eczema","author":"Molin S","year":"2024","unstructured":"Molin S, Cr\u00e9py M, Fargnoli M, et al., editors. Health care visits and out-of-pocket costs in people with chronic hand eczema. Barcelona, Spain: International Society for Pharmacoeconomics and Outcomes Research; 2024."},{"key":"e_1_3_8_11_1","volume-title":"2025 Fall Clinical Dermatology Conference, Las Vegas, NV, USA","author":"Armstrong A","year":"2025","unstructured":"Armstrong A, Burne R, Sawad A, et al. Demographics, clinical, and treatment characteristics of patients with moderate to severe Chronic Hand Eczema in the United States \u2013 A retrospective claims analysis. 2025 Fall Clinical Dermatology Conference, Las Vegas, NV, USA; 2025."},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01534-8"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2023.11.004"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-026-01008-3"},{"key":"e_1_3_8_15_1","unstructured":"Cibinqo. Prescribing information. Pfizer Inc; 2023 [cited 2025 Oct 30]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/213871s004lblcorrected.pdf."},{"key":"e_1_3_8_16_1","unstructured":"Opzelura. Prescribing information. Incyte; 2025 [cited 2025 Oct 30]. https:\/\/www.opzelura.com\/opzelura-prescribing-information"},{"key":"e_1_3_8_17_1","unstructured":"Rinvoq. Prescribing information. AbbVie Inc.; 2025 [cited 2025 Oct 30]. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf"},{"key":"e_1_3_8_18_1","unstructured":"Dupixent. Prescribing information. Regeneron Pharmaceuticals Inc.; 2025 [cited 2025 Oct 30]. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S292504"},{"key":"e_1_3_8_20_1","unstructured":"Anzupgo. Prescribing information. LEO Pharma Inc.; 2025 [cited 2025 Oct 30]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219155s000lbl.pdf"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01027-4"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.03.008"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13804"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.13113"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14974"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14477"},{"key":"e_1_3_8_27_1","unstructured":"Centers for Medicare & Medicaid Services (CMS). Physician fee schedule. 2025. [cited 2025 Aug 13]. www.cms.gov\/medicare\/physician-fee-schedule\/search?Y=0&T=4&HT=0&CT=3&H1=99213&M=5"},{"key":"e_1_3_8_28_1","unstructured":"Merative. Micromedex RED BOOK. 2022. https:\/\/www.merative.com\/documents\/micromedex-red-book"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12765"},{"key":"#cr-split#-e_1_3_8_30_1.1","unstructured":"OECD Statistics. Consumer Price Indices (CPIs HICPs). COICOP 1999"},{"key":"#cr-split#-e_1_3_8_30_1.2","unstructured":"2025 [cited 2025 May 13]. https:\/\/stats.oecd.org\/index.aspx?DataSetCode=PRICES_CPI#"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201703-259OC"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S233486"},{"key":"e_1_3_8_33_1","unstructured":"Medicaid. Affordable care act federal upper limits. 2024. [cited 2024 July 20]. https:\/\/data.medicaid.gov\/dataset\/ce4cf49b-a21b-5a53-bbc3-509414940847\/data?conditions[0][property]=year&conditions[0][value]=2023&conditions[0][operator]=%3D&conditions[1][property]=month&conditions[1][value]=11&conditions[1][operator]=%3D#main-content"},{"key":"e_1_3_8_34_1","unstructured":"Acyclovir. Prescribing information. Apotex Inc.; 2024. [cited 2025 May 12]. https:\/\/www.accessdata.fda.gov\/spl\/data\/a7fd298b-3914-4316-8484-2d3ae188221a\/a7fd298b-3914-4316-8484-2d3ae188221a.xml#_b3155753-d45e-afc1-5ce7-30e5e45279c6."},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14020192"},{"key":"e_1_3_8_36_1","unstructured":"Amoxil. Prescribing information. Dr. Reddy\u2019s Laboratories Tennessee LLC; 2015 [cited 2025 Nov 7]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/50542s02950754s01950760s01950761s016lbl.pdf"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.10.1416"},{"key":"e_1_3_8_39_1","unstructured":"Consumer Price Index. Organization for economic co-operation and development; 2025. https:\/\/stats.oecd.org\/index.aspx?DataSetCode=PRICES_CPI#"},{"key":"e_1_3_8_40_1","unstructured":"Micromedex. CIBINQO red book; 2024 [cited 2025 May 12]. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/6B3BAB\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/FF1887\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=CIBINQO&searchType=redbookProductName&searchTermId=52597&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Ecibin"},{"key":"e_1_3_8_41_1","unstructured":"Micromedex. OPZELURA red book; 2024. [cited 2025 May 12]. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/C8FECB\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/7BE18D\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=OPZELURA&searchType=redbookProductName&searchTermId=52255&searchContent=%24searchContent&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5EOPZELURA"},{"key":"e_1_3_8_42_1","unstructured":"Micromedex. RINVOQ red book; 2024. [cited 2025 May 12]. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/505269\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/C3B042\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=RINVOQ&searchType=redbookProductName&searchTermId=49460&searchContent=%24searchContent&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5ERinvoq"},{"key":"e_1_3_8_43_1","unstructured":"Micromedex. DUPIXENT PFS RED BOOK; 2024. [cited 2025 May 12]. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/CS\/97238B\/ND_PR\/evidencexpert\/ND_P\/evidencexpert\/DUPLICATIONSHIELDSYNC\/EA8DE6\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_AppProduct\/evidencexpert\/ND_T\/evidencexpert\/PFActionId\/redbook.ShowProductSearchResults?SearchTerm=DUPIXENT%20PFS&searchType=redbookProductName&searchTermId=55441&searchContent=%24searchContent&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5EDUPIxen"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00892-5"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2005.11.1.66"},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01475-2"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.049"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.09.032"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-026-01755-5"},{"issue":"7","key":"e_1_3_8_50_1","first-page":"750","article-title":"Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis","volume":"17","author":"Zimmermann M","year":"2018","unstructured":"Zimmermann M, Rind D, Chapman R, et al. Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drugs Dermatol. 2018;17(7):750\u2013756.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_8_51_1","unstructured":"NICE. Delgocitinib for treating moderate to severe chronic hand eczema: Technology appraisal guidance. NIfHaCE; 2025 [cited 2026 Feb 4]. https:\/\/www.nice.org.uk\/guidance\/ta1107\/chapter\/1-Recommendations"},{"key":"e_1_3_8_52_1","article-title":"Reimbursement recommendation: delgocitinib (Anzupgo)","author":"CDA-AMC","year":"2025","unstructured":"CDA-AMC. Reimbursement recommendation: delgocitinib (Anzupgo). Can J Health Technol. 2025; [cited 2026 Feb 4]. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2025\/SR0875-Anzupgo_Recommendation.pdf","journal-title":"Can J Health Technol"},{"key":"e_1_3_8_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_3_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085"},{"key":"e_1_3_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.09.060"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2675851","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:02:19Z","timestamp":1779904939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2675851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2675851"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2675851","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}